{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:42:31Z","timestamp":1788838951543,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1810648"],"award-info":[{"award-number":["W81XWH1810648"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F&amp;#x00F6;rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95229-x","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:22:36Z","timestamp":1744125756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel serum biomarker associations with 7 Tesla MRI-defined cortical lesions, leptomeningeal enhancement, and deep gray matter volume in early multiple sclerosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Andrei","family":"Miclea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrishti","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Lokhande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Quattrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renxin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"95229_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan, C., Kaskow, B. J. & Weiner, H. L. Multiple sclerosis: Mechanisms and immunotherapy. Neuron 97, 742\u2013768 (2018).","journal-title":"Neuron"},{"key":"95229_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur, C. et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 80, 151\u2013160 (2023).","journal-title":"JAMA Neurol."},{"key":"95229_CR3","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","volume":"128","author":"A Kutzelnigg","year":"2005","unstructured":"Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705\u20132712 (2005).","journal-title":"Brain"},{"key":"95229_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089\u20131104 (2007).","journal-title":"Brain"},{"key":"95229_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ana.25365","volume":"84","author":"RJ Bevan","year":"2018","unstructured":"Bevan, R. J. et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann. Neurol. 84, 829\u2013842 (2018).","journal-title":"Ann. Neurol."},{"key":"95229_CR6","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","volume":"365","author":"CF Lucchinetti","year":"2011","unstructured":"Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188\u20132197 (2011).","journal-title":"N. Engl. J. Med."},{"key":"95229_CR7","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell, O. W. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755\u20132771 (2011).","journal-title":"Brain"},{"key":"95229_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi, R. et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann. Neurol. 83, 739\u2013755 (2018).","journal-title":"Ann. Neurol."},{"key":"95229_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1352458519885106","volume":"26","author":"J Zurawski","year":"2020","unstructured":"Zurawski, J. et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult. Scler. J. 26, 177\u2013187 (2020).","journal-title":"Mult. Scler. J."},{"key":"95229_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/jon.12444","volume":"27","author":"DM Harrison","year":"2017","unstructured":"Harrison, D. M. et al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. J. Neuroimaging 27, 461\u2013468 (2017).","journal-title":"J. Neuroimaging"},{"key":"95229_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3174\/ajnr.A5796","volume":"39","author":"SN Jonas","year":"2018","unstructured":"Jonas, S. N., Izbudak, I., Frazier, A. A. & Harrison, D. M. Longitudinal persistence of meningeal enhancement on postcontrast 7T 3D-FLAIR MRI in multiple sclerosis. Am. J. Neuroradiol. 39, 1799\u20131805 (2018).","journal-title":"Am. J. Neuroradiol."},{"key":"95229_CR12","doi-asserted-by":"publisher","first-page":"102939","DOI":"10.1016\/j.nicl.2022.102939","volume":"33","author":"BV Ineichen","year":"2022","unstructured":"Ineichen, B. V., Tsagkas, C., Absinta, M. & Reich, D. S. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and meta-analysis. Neuroimage Clin. 33, 102939 (2022).","journal-title":"Neuroimage Clin."},{"key":"95229_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/13524585211069167","volume":"28","author":"ES Beck","year":"2022","unstructured":"Beck, E. S. et al. Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis. Mult. Scler. 28, 1351\u20131363 (2022).","journal-title":"Mult. Scler."},{"key":"95229_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1148\/radiol.2019181719","volume":"291","author":"CA Treaba","year":"2019","unstructured":"Treaba, C. A. et al. Longitudinal characterization of cortical lesion development and evolution in multiple sclerosis with 7.0-T MRI. Radiology 291, 710\u2013749 (2019).","journal-title":"Radiology"},{"key":"95229_CR15","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/brain\/aws246","volume":"135","author":"M Calabrese","year":"2012","unstructured":"Calabrese, M. et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135, 2952\u20132961 (2012).","journal-title":"Brain"},{"key":"95229_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ana.25145","volume":"83","author":"A Eshaghi","year":"2018","unstructured":"Eshaghi, A. et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann. Neurol. 83, 210\u2013222 (2018).","journal-title":"Ann. Neurol."},{"key":"95229_CR17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00415-020-09841-0","volume":"267","author":"C Engl","year":"2020","unstructured":"Engl, C. et al. Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. J. Neurol. 267, 2307 (2020).","journal-title":"J. Neurol."},{"key":"95229_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/biom12060800","volume":"12","author":"C Rodriguez-mogeda","year":"2022","unstructured":"Rodriguez-mogeda, C. et al. Breaching brain barriers: B cell migration in multiple sclerosis. Biomolecules 12, 800 (2022).","journal-title":"Biomolecules"},{"key":"95229_CR19","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.638","volume":"5","author":"T Chitnis","year":"2018","unstructured":"Chitnis, T. et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann. Clin. Transl. Neurol. 5, 1478\u20131491 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"95229_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33158-8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak, A., Huss, A., Kassubek, J., Tumani, H. & Otto, M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-018-33158-8 (2018).","journal-title":"Sci. Rep."},{"key":"95229_CR21","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/brain\/aww037","volume":"139","author":"ID Kilsdonk","year":"2016","unstructured":"Kilsdonk, I. D. et al. Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: A post-mortem verification study. Brain 139, 1472\u20131481 (2016).","journal-title":"Brain"},{"key":"95229_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.autrev.2006.02.012","volume":"5","author":"SA Gauthier","year":"2006","unstructured":"Gauthier, S. A., Glanz, B. I., Mandel, M. & Weiner, H. L. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun. Rev. 5, 532\u2013536 (2006).","journal-title":"Autoimmun. Rev."},{"key":"95229_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"95229_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-017-0949-4","volume":"17","author":"R Chu","year":"2017","unstructured":"Chu, R., Hurwitz, S., Tauhid, S. & Bakshi, R. Automated segmentation of cerebral deep gray matter from MRI scans: Effect of field strength on sensitivity and reliability. BMC Neurol. 17, 1\u201310 (2017).","journal-title":"BMC Neurol."},{"key":"95229_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1674-2","volume":"16","author":"T Ziemssen","year":"2019","unstructured":"Ziemssen, T., Akg\u00fcn, K. & Br\u00fcck, W. Molecular biomarkers in multiple sclerosis. J. Neuroinflamm. 16, 1\u201311 (2019).","journal-title":"J. Neuroinflamm."},{"key":"95229_CR26","doi-asserted-by":"publisher","first-page":"1175230","DOI":"10.3389\/fmolb.2023.1175230","volume":"10","author":"B Fazeli","year":"2023","unstructured":"Fazeli, B. et al. Development of an ultrasensitive microfluidic assay for the analysis of glial fibrillary acidic protein (GFAP) in blood. Front. Mol. Biosci. 10, 1175230 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"95229_CR27","doi-asserted-by":"publisher","first-page":"105412","DOI":"10.1016\/j.msard.2023.105412","volume":"82","author":"D Vecchio","year":"2024","unstructured":"Vecchio, D. et al. Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA\u2122, Ella\u2122, and Lumipulse\u2122 in multiple sclerosis na\u00efve patients. Mult. Scler. Relat. Disord. 82, 105412 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"95229_CR28","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1212\/WNL.0000000000000908","volume":"83","author":"AK Huber","year":"2014","unstructured":"Huber, A. K. et al. Dysregulation of the IL-23\/IL-17 axis and myeloid factors in secondary progressive MS. Neurology 83, 1500 (2014).","journal-title":"Neurology"},{"key":"95229_CR29","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.4049\/jimmunol.173.11.6676","volume":"173","author":"CS Park","year":"2004","unstructured":"Park, C. S., Yoon, S. O., Armitage, R. J. & Choi, Y. S. Follicular Dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form. J. Immunol. 173, 6676\u20136683 (2004).","journal-title":"J. Immunol."},{"key":"95229_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0785-2","author":"M Puthenparampil","year":"2017","unstructured":"Puthenparampil, M. et al. BAFF index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. J. Neuroinflamm. https:\/\/doi.org\/10.1186\/s12974-016-0785-2 (2017).","journal-title":"J. Neuroinflamm."},{"key":"95229_CR31","unstructured":"Luminex Assay User Guide. https:\/\/resources.bio-techne.com\/bio-techne-assets\/images\/literature\/br-luminex-assay-users-guide.pdf?utm_source."},{"key":"95229_CR32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/cercor\/bht017","volume":"24","author":"H Oh","year":"2014","unstructured":"Oh, H., Madison, C., Villeneuve, S., Markley, C. & Jagust, W. J. Association of gray matter atrophy with Age, \u03b2-amyloid, and cognition in aging. Cereb. Cortex 24, 1609\u20131618 (2014).","journal-title":"Cereb. Cortex"},{"key":"95229_CR33","unstructured":"Olink Target 96 Neurology Panels-Olink. https:\/\/www.olink.com\/products-services\/target\/neurology-panel\/."},{"key":"95229_CR34","doi-asserted-by":"publisher","first-page":"889647","DOI":"10.3389\/fneur.2022.889647","volume":"13","author":"BC Carlyle","year":"2022","unstructured":"Carlyle, B. C. et al. Technical performance evaluation of olink proximity extension assay for blood-based biomarker discovery in longitudinal studies of Alzheimer\u2019s disease. Front. Neurol. 13, 889647 (2022).","journal-title":"Front. Neurol."},{"key":"95229_CR35","unstructured":"Kim, S. Package \u2018ppcor\u2019 type package title partial and semi-partial (part) correlation. (2022)."},{"key":"95229_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200265","author":"D Marastoni","year":"2024","unstructured":"Marastoni, D. et al. Association of levels of CSF osteopontin with cortical atrophy and disability in early multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200265 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"95229_CR37","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1002188","volume":"185","author":"P Saikali","year":"2010","unstructured":"Saikali, P., Antel, J. P., Pittet, C. L., Newcombe, J. & Arbour, N. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J. Immunol. 185, 5693\u20135703 (2010).","journal-title":"J. Immunol."},{"key":"95229_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1056\/NEJM199108153250704","volume":"325","author":"MK Sharief","year":"1991","unstructured":"Sharief, M. K. & Hentges, R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325, 467\u2013472 (1991).","journal-title":"N. Engl. J. Med."},{"key":"95229_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4049\/jimmunol.171.2.547","volume":"171","author":"KA Vora","year":"2003","unstructured":"Vora, K. A. et al. Cutting edge: Germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J. Immunol. 171, 547\u2013551 (2003).","journal-title":"J. Immunol."},{"key":"95229_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio, L. et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707\u2013714 (2010).","journal-title":"Arch. Neurol."},{"key":"95229_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/hmg\/ddv473","volume":"25","author":"M Comabella","year":"2016","unstructured":"Comabella, M. et al. MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Hum. Mol. Genet. 25, 308\u2013316 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"95229_CR42","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1212\/NXI.0000000000000943","volume":"8","author":"D Johansson","year":"2021","unstructured":"Johansson, D. et al. Mass CYtometry of CSF identifies an MS-associated B-cell population. Neurol. Neuroimmunol. Neuroinflamm. 8, e943 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"95229_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2016.4237","volume":"74","author":"J Zurawski","year":"2017","unstructured":"Zurawski, J., Lassmann, H. & Bakshi, R. Use of magnetic resonance imaging to visualize leptomeningeal inflammation in patients with multiple sclerosis: A review. JAMA Neurol. 74, 100\u2013109 (2017).","journal-title":"JAMA Neurol."},{"key":"95229_CR44","doi-asserted-by":"publisher","first-page":"112164","DOI":"10.1016\/j.celrep.2023.112164","volume":"42","author":"Q Zuo","year":"2023","unstructured":"Zuo, Q. et al. Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis. Cell Rep. 42, 112164 (2023).","journal-title":"Cell Rep."},{"key":"95229_CR45","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1096\/fj.201600611R","volume":"30","author":"M Garc\u00eda-Barros","year":"2016","unstructured":"Garc\u00eda-Barros, M. et al. Role of neutral ceramidase in colon cancer. FASEB J. 30, 4159\u20134171 (2016).","journal-title":"FASEB J."},{"key":"95229_CR46","doi-asserted-by":"publisher","first-page":"110560","DOI":"10.1016\/j.celrep.2022.110560","volume":"38","author":"R Sun","year":"2022","unstructured":"Sun, R. et al. Neutral ceramidase-dependent regulation of macrophage metabolism directs intestinal immune homeostasis and controls enteric infection. Cell Rep. 38, 110560 (2022).","journal-title":"Cell Rep."},{"key":"95229_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/19336918.2017.1288788","volume":"12","author":"KTE Kleijer","year":"2018","unstructured":"Kleijer, K. T. E. et al. Structural abnormalities in the primary somatosensory cortex and a normal behavioral profile in Contactin-5 deficient mice. Cell Adh. Migr. 12, 5\u201318 (2018).","journal-title":"Cell Adh. Migr."},{"key":"95229_CR48","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/brain\/awaa084","volume":"143","author":"S Malhotra","year":"2020","unstructured":"Malhotra, S. et al. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain 143, 1414\u20131430 (2020).","journal-title":"Brain"},{"key":"95229_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65038-5","author":"S Ahmad","year":"2020","unstructured":"Ahmad, S. et al. CDH6 and HAGH protein levels in plasma associate with Alzheimer\u2019s disease in APOE \u03b54 carriers. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-65038-5 (2020).","journal-title":"Sci. Rep."},{"key":"95229_CR50","doi-asserted-by":"publisher","first-page":"106695","DOI":"10.1016\/j.intimp.2020.106695","volume":"86","author":"EA Kang","year":"2020","unstructured":"Kang, E. A. et al. Soluble Siglec-9 alleviates intestinal inflammation through inhibition of the NF-\u03baB pathway. Int. Immunopharmacol. 86, 106695 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"95229_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00391","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Nuclear factor \u03baB (NF-\u03baB)-mediated inflammation in multiple sclerosis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00391 (2020).","journal-title":"Front. Immunol."},{"key":"95229_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nn.3588","volume":"17","author":"JL Huynh","year":"2014","unstructured":"Huynh, J. L. et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat. Neurosci. 17, 121\u2013130 (2014).","journal-title":"Nat. Neurosci."},{"key":"95229_CR53","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1212\/WNL.0000000000200006","volume":"98","author":"IA Lie","year":"2022","unstructured":"Lie, I. A. et al. Relationship between white matter lesions and gray matter atrophy in multiple sclerosis. Neurology 98, E1562\u2013E1573 (2022).","journal-title":"Neurology"},{"key":"95229_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458518819380","volume":"26","author":"H H\u00f6gel","year":"2020","unstructured":"H\u00f6gel, H. et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult. Scler. 26, 210\u2013219 (2020).","journal-title":"Mult. Scler."},{"key":"95229_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001074","author":"\u00c1J Cruz-Gomez","year":"2021","unstructured":"Cruz-Gomez, \u00c1. J. et al. Cortical thickness and serum NfL explain cognitive dysfunction in newly diagnosed patients with multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001074 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"95229_CR56","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1177\/1352458516643396","volume":"22","author":"SK Ludwin","year":"2016","unstructured":"Ludwin, S. K., Rao, V. T. S., Moore, C. S. & Antel, J. P. Astrocytes in multiple sclerosis. Mult. Scler. 22, 1114\u20131124 (2016).","journal-title":"Mult. Scler."},{"key":"95229_CR57","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrneurol.2010.93","volume":"6","author":"M Calabrese","year":"2010","unstructured":"Calabrese, M., Filippi, M. & Gallo, P. Cortical lesions in multiple sclerosis. Nat. Rev. Neurol. 6, 438\u2013444 (2010).","journal-title":"Nat. Rev. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95229-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95229-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95229-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:17:21Z","timestamp":1744219041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95229-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95229"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95229-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM has received research support from the Swiss National Science Foundation (SNSF). Also, he has received personal compensation from Strategy& (part of PwC) and High-Tech Grunderfonds. JZ reports research support from the Elizabeth Kremer Foundation, Novartis, NIH, I-Mab Biopharma and the Race to Erase MS Foundation. BCH reports research support from Bristol Myers Squibb, Novartis and Genzyme. SS reports no disclosures. HL reports no disclosures. MQ reports no disclosures. RC reports no disclosures. HLW - Dr. Weiner has received research support from NIH, NMSS, EMD Serono, Novartis, Sanofi Genzyme, Teva Neurosciences, and Verily Life Sciences, and personal and consulting fees from Genentech, Tiziana Life Sciences, Tilos Therapeutics, IM Therapeutics, vTv Therapeutics and MedDay Pharmaceuticals. RB - Dr. Bakshi has received speaking honoraria from EMD Serono and Sanofi and research support from Bristol Myers Squibb, EMD Serono, and Novartis. TC - Dr. Chitnis has received compensation for speaking engagements from Prime Education, LLC. Dr. Chitnis has received research support from the National Institutes of Health, National MS Society, US Department of Defense, Sumaira Foundation, Brainstorm Cell Therapeutics, Bristol Myers Squibb, Genentech, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Massachusetts Life Sciences Center, Novartis Pharmaceuticals, Octave Bioscience, Sanofi Genzyme, Tiziana Life Sciences, and Wesley Clover International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12032"}}